Replies to post #248589 on Biotech Values

[DewDiligence]

Clearly, there is a regulatory pathway_for_a COVID antiviral, but the phase-3 trial design selected by AVIR is not the way to go, IMO.

[dewophile]

All that money may be burning a hole in their pocket. Why run a hep C trial in this day and age?

[vinmantoo]

AVIR modifies phase-3 protocol for COVID antiviral, bemnifosbuvir—(f/k/a AT-527):

https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-reports-second-quarter-2023-financial

How can that be? Jake assured us that a phase 3 trial for anti-Covid drugs can't be run because Paxlovid is approved. Jake better rush in and tell AVIR and the FDA that a phase 3 trial can't be run.

[DewDiligence]

AVIR phase-3 COVID update:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.